Navigation Links
Valeant Pharmaceuticals Prices Public Offering Of Common Shares
Date:6/18/2013

LAVAL, Quebec, June 18, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) has priced its previously announced public offering of common shares (the "Offering"). Pursuant to the Offering, the Company will issue 23,529,412 common shares at a price of $85.00 per share, for aggregate gross proceeds of approximately $2.0 billion. The Company will file a final prospectus supplement to its effective shelf registration statement on Form S-3 and will make a similar filing with the securities regulatory authorities in each of the provinces of Canada.  Closing of the Offering is expected to occur on or about June 24, 2013.

The Company has also granted to the underwriters of the Offering an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase additional common shares equal to up to 15% of the common shares initially sold.

The Company intends to use the net proceeds from the Offering, together with debt financing, to fund (i) the consideration of its previously disclosed acquisition (the "Merger") of Bausch + Lomb Holdings Incorporated ("B+L"), (ii) the fees and expenses incurred in connection with the Merger; and (iii) the repayment or retirement of B+L's outstanding debt.  If the Merger were not to close for any reason, the proceeds of the Offering will be used for general corporate purposes, which may include providing working capital, funding capital expenditures or for making one or more future acquisitions.

Goldman, Sachs & Co. will act as sole manager of the Offering outside of Canada and Goldman Sachs Canada Inc. will act as sole manager of the Offering in Canada. 

A copy of the final prospectus supplement and accompanying prospectus relating to the Offering in the United States (the "U.S. Prospectus") will be available on EDGAR at www.sec.gov and a copy of the final prospectus supplement and accompanying base shelf prospectus relating to the Offering in Canada (the "Canadian Prospectus") will be available on SEDAR at www.sedar.com.  Alternatively, a copy of the U.S. Prospectus may be obtained from Goldman, Sachs & Co. at 200 West Street, New York, New York 10282, Attn: Prospectus Department, telephone: 866-471-2526, facsimile: 212-902-9316, email: prospectus-ny@ny.email.gs.com and a copy of the Canadian Prospectus may be obtained from Goldman Sachs Canada Inc. at  77 King Street West, Suite 3400, Toronto, Ontario M5K 1B7, Attn: Prospectus Department, telephone: 866-471-2526, facsimile: 212-902-9316, email: prospectus-ny@ny.email.gs.com.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements

This press release may contain forward-looking statements, including, but not limited to those related to the Company's expectations in connection with the Offering  the intended use of proceeds and the acquisition and financing of B+L. Forward looking statements can generally be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "should," "would," "intend," "seem," "potential," "appear," "continue," "future," believe," "estimate," "forecast," "project," variations of such words or other words that convey uncertainty of future events or outcome, although not all forward-looking statements contain these identifying words. Our forward-looking statements are subject to known and unknown risks and uncertainties, many of which are outside of our control and could cause actual results to differ materially and adversely from those expressed or implied by such statements. Those risks include, but are not limited to: our future economic performance, operating results, financial condition, capital resources or prospects; projections of revenue, expenses, income and losses, earnings (losses) per share, capital expenditures, dividends, growth rates or other financial items; market or industry trends, legal or regulatory developments; future events; the anticipated effect of acquisitions, litigation, new (or changes to existing) laws, regulations or accounting principles or other matters on our business, economic performance, operating results, financial condition, capital resources or prospects; our plans, objectives and strategies for future operations or otherwise; and our expectations and beliefs. Information concerning potential factors that could affect the Company's financial results is included in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
2. Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus
3. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
4. Valeant Pharmaceuticals Announces 2013 Annual Meeting Results
5. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
6. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
7. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
8. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
9. Valeant Pharmaceuticals Provides Efinconazole Update
10. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
11. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017  CANTEL MEDICAL CORP. (NYSE: ... President and CEO, will be presenting at the 16 th ... Grand Central Hotel in New York . ... at 3:00 p.m. ET. In addition, management will be available ... A live audio webcast will be available via the investor ...
(Date:3/22/2017)... 2017  Ablation is the minimally invasive therapeutic ... of purposes, from cancerous or diseased tissue removal, ... in atrial fibrillation and others. The growing adoption ... to innovate and improvise existing ablation technologies for ... global market is expected to grow at high ...
(Date:3/22/2017)... LINCOLN, Mass. , March 22, 2017 /PRNewswire/ ... applying mechanistic modeling to drug research and development, ... QSP Day 2017.  QSP Day 2017 is a ... with the quantitative systems pharmacology (QSP) community. The ... mathematical modeling is de-risking and accelerating drug research ...
Breaking Medicine Technology:
(Date:3/22/2017)... NJ (PRWEB) , ... March 22, 2017 , ... ... Group, the nation’s leading digital and print media enterprise focused on cancer patients, ... video content, has released a special 12-part educational video series, “No Ifs, Ands, ...
(Date:3/22/2017)... ... March 22, 2017 , ... An intensive search of the ... HIV, reports Leslie Norins, MD, PhD. He says investigating this possibility, is ... Zika virus and in new infections with HIV. , His findings appear ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Last year, ... to a US Department of Agriculture report. While excess dairy can be caused ... a role. Lactose sensitivity is the inability to properly digest lactose, a sugar found ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a Long Island ... County region, is embarking on a combined charity effort with the Great Neck Breast ... last 25 years, the Great Neck Breast Cancer Coalition has worked to support breast ...
(Date:3/22/2017)... ... March 22, 2017 , ... The ... related services to families and business owners in the greater Nassau County area, ... & Lymphoma Society. , Every 3 minutes, someone in America is diagnosed with ...
Breaking Medicine News(10 mins):